GNbAC1 is a humanized monoclonal antibody targeting MSRV-Env, an endogenous retroviral protein, which is expressed in multiple sclerosis (MS) lesions, is pro-inflammatory and inhibits oligodendrocyte precursor cell differentiation. This paper describes the open-label extension up to 12 months of a trial testing GNbAC1 in 10 MS patients at 2 and 6 mg/kg. The primary objective was to assess GNbAC1 safety, and other objectives were pharmacokinetic and pharmacodynamic assessments. During the extended study, no safety issues occurred in the 8 remaining patients. No anti-GNbAC1 antibodies were detected. GNbAC1 appears well tolerated.
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients -A twelve month follow-up GNbAC1 is a recombinant humanized IgG4/kappa monoclonal antibody (mAb) which binds a protein called MSRV-Env expressed by genes from the human endogenous retrovirus type W family (HERV-W) also named "Multiple Sclerosis associated Retrovirus" (MSRV) (Perron et al., 1997) .
Several studies have demonstrated links between the expression of MSRV-Env and multiple sclerosis (MS); in particular immunohistochemical analyses of post-mortem brain tissue from MS patients localize the MSRV-Env protein to MS plaques with a higher level of protein expression in active plaques compared to inactive plaques (Mameli et al., 2007; Perron et al., 2012) .
In MS pathogenesis, dysregulation of both the innate and adaptive immune systems is considered as the main triggering and/or exacerbating factor. MSRV-Env activates Toll-like receptor 4 (TLR4) and has a proinflammatory effect mediated through its interaction with TLR4 in peripheral blood mononuclear cell (PBMC) cultures (Rolland et al., 2006) . Another effect of MSRV-Env is the blockade of the oligodendrocyte differentiation necessary for the remyelination process, also mediated by an interaction with TLR4 on oligodendrocyte precursor cells (OPCs) (Kremer et al., 2013) . Based on the ability of MSRV-Env to activate the innate immune system and given its direct toxicity on OPCs, MSRV-Env is a relevant therapeutic target for MS.
The mAb GNbAC1 was developed as a MSRV-Env antagonist. Preclinical studies showed that GNbAC1 neutralizes the MSRV-Env target (Rolland et al., 2006; Kremer et al., 2014) . GNbAC1 had been studied first in a phase I clinical trial in 33 healthy subjects, showing a good safety as well as a linear pharmacokinetics (Curtin et al., 2012) . The goals of the present placebo controlled dose escalation study with an open-label
